In target discovery, single-gene knockouts are a powerful starting point, but they rarely capture the full reality of complex human disease. A standard CRISPR screen might yield a promising single-gene hit, but block just one pathway and the disease simply reroutes. To develop truly transformative interventions, like combination therapies or drugs that trigger synthetic lethality to overcome drug resistance, discovery programs must move beyond single-gene knockouts to hit multiple targets simultaneously. But mapping this genetic interaction manifold in the physical lab creates an immediate scaling crisis worth approx. $500K-$700K.

To bypass the massive cost and limitations of physical screens and wet lab experiments, leading biotechs are moving target discovery and validation layer entirely in-silico. By leveraging Elucidata’s El-Perturb, our advanced perturbation prediction model, computational biology teams can forecast the cellular response to complex, multi-gene knockouts across unseen contexts computationally to isolate target pairs and protect million dollar validation budgets before a single physical assay is run.

The Math Problem of CRISPR Screens

Running a genome-wide CRISPR screen for a single target is expensive but achievable. Moving to combinatorial screening, however, introduces a scaling bottleneck for the physical lab:

• The Combinatorial Explosion: The human genome has roughly 20,000 genes. Testing every possible two-gene combination (double knockouts) requires running nearly 200 million assays. Moving to triple combinations pushes that number over 1.3 trillion.
• The Resource Wall: No biotech company has the physical automation, time, or validation budget to screen hundreds of millions of combinations in the wet lab using dual-guide RNA vectors.
• The Bias Compromise: Forced by these budget constraints, teams often shrink their combination screens to a tiny, pre-selected handful of targets. This heavy bias means the most transformative, non-obvious synergistic pairs are left completely undiscovered.

The Multiomics Data Swamp

Even when teams manage to physically screen a sub-set of combinations, traditional viability screens only answer a binary question: Did the cell live or die?

To understand why a combination works and whether it will trigger off-target toxicity, the industry is shifting to high-dimensional readouts like single-cell Perturb-seq.

However, this creates a new bottleneck. Integrating transcriptomics with broader multiomics data (like proteomics and epigenetics) to decode complex epistatic interactions (where the effect of one gene depends on another) generates a massive, overlapping data swamp. Standard bioinformatic pipelines simply cannot resolve this multiomics complexity.

The OOD Cliff in Combinatorial Space

To solve this math problem, computational biology teams are turning to AI models to simulate these screens. But there is a trap: many highly publicized foundation models fail spectacularly at this specific task.

If standard AI models struggle with Out-of-Distribution (OOD) failures on single targets in novel cell lines, they completely break down when asked to predict the overlapping biology of two unseen targets.

Because the assumption that training and testing data come from the same distribution is heavily violated in combinatorial space, typical model performance falls off a steep cliff. Relying on standard foundation models to predict complex synthetic lethality risks advancing costly false positives.

How Elucidata is Solving the CRISPR and Wet Lab bottlenecks

To bypass the combinatorial trap, we replace physical guesswork with a defensible, in-silico pipeline:

1: Structuring Biological Context (Polly KG)- Before you can predict how a combination behaves, you need a foundation of biological truth. The Polly Knowledge Graph structures complex multiomics data into actionable biological context.

• Traversing 31 million nodes and 60 million relationships, it integrates transcriptomic, proteomic, and genomic layers.
• It verifies whether a target space maps to established disease mechanisms, avoids shared toxicity pathways, and is realistically druggable.

2: Simulating transcriptional responses In-Silico -  

• El-Perturb learns from foundational single-perturbation data to accurately forecast the high-dimensional response of multi-gene combinations.
• To ensure these predictions hold up in unseen biological territory, we augment the model with El-Prior. This architecture-agnostic prediction framework utilizes explicit multi-context training to make the underlying model inherently OOD-aware.

3: The Honest Confidence Scoring- AI hallucination in multi-target screening is a financial risk. To protect your validation budget, El-Perturb applies a strict confidence score to every prediction.

• If a predicted interaction steps into completely novel biological territory where the model is less certain, it is explicitly flagged.
• This clearly signals to your discovery team exactly where targeted experimental validation is required.

You no longer walk into a program review with a fragile, biased list of targets. You walk in with a defensible shortlist of confident targets, backed by structured multiomics context, OOD-aware predictions, and an honest confidence level that protects downstream validation budgets.

Connect with us and Discover how El-Perturb, our in-silico prediction model can solve the critical bottlenecks of CRISPR screens and transform your target discovery pipeline.

‍